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ABSTRACT 
Background 
The lack of patient care and utilisation data impairs the ability of hospital and clinic 
administrators to make informed, data-driven policy choices. This concern is particularly acute 
with HIV/AIDS, given both the striking growth in the local epidemic over the last two years and 
the high level of HIV -related health expenditures shouldered by the provincial medical system in 
the Western Cape province of South Africa. 
Methods 
A retrospective chart review was conducted to capture clinical and utilisation data of from 
a sample of 59 inpatients, who were admitted to a township secondary hospital near Cape Town, 
South Africa during 1997. Three years of data were abstracted and analysed. 
Results 
This sample was exclusively comprised of Black and so-called Coloured inpatients. 
Patients in the sample had a mean age of 35 and roughly 63% were female. Mean length of stay 
was 5.2 and 4.0 days for WHO stage 3 and 4, respectively, though the estimated variance was 
large. 
The clinical picture proved interesting. Tuberculosis was present in roughly 66% and 
38% of stage 3 and 4 patients, respectively. The frequency of gastrointestinal complaints was 
also high, as was the occurrence of suspected meningitic illnesses and other neurological 
complications. Co-trimoxazole use was strikingly low, particularly given the documented 
survival benefit and low cost of the dIJ.!g. Patients who initially present in stage 4 HIV disease 
lived a median of20 days; this estimate has a relatively narrow confidence interval. 
Cost of care estimates were generated from these and other data. The general cost per 
inpatient day at this facility was R504. The patient-specific utilisation was approximately R151 
for patients in stage 3 and RI13 for patients initially presenting in stage 4. Lab tests constituted 
the largest share of patient-specific utilisation, followed by medications and radiology. The 
general costs comprised about 80% of total costs. 
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Conclusions & Recommendations 
The confirmed HIV -infected patients at this facility represent about 2% of total inpatient 
volume during the study period. Many HIV-diagnoses were new, and a substantial portion of 
HIV -tests were motivated by clinical or presumptive diagnoses. Differences in survival between 
this sample and that reported elsewhere in South Africa may be related to access to specialty 
outpatient care. 
Based on this study, I offer the following operational recommendations for local medical 
superintendents and other health policy decision-makers: 
1. Increase the use ofco-trimoxazole prophylaxis in stages 3 and 4 ofHIV disease. 
2. Review treatment protocol for patients initially presenting at WHO stage 4. 
3. Focus on pain management/palliative care education among clinicians. 
4. Better utilise home-based care alternatives for terminal/moribund patients. 
5. Reduce specific laboratory/antibiotic utilisation. 
6. Increase bed availability at non-acute, chronic care facilities 
7. Bridge the current gaps in information technology. 
8. Introduce unique patient identifiers (UPls). 
9. Improve documentation in patient charts. 
The demand for HIV -related health care services will increase as the epidemic grows in this 
province. These recommendations may improve the capacity of the health system to address 
these needs and improve patient health outcomes. 
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I. INTRODUCTION 
The lack of patient care and utilisation data impairs the ability of hospital and clinic 
administrators to make informed, data-driven policy choices. This concern is particularly acute 
with HIV/AIDS, given both the striking growth in the local epidemic over the last two years and 
the high level ofHIV -related health expenditures shouldered by the provincial medical system. 
Frustrated by the scarcity of local data, I attempted to characterise an HIV-inpatient 
population and related expenditures within a secondary acute hospital that serves a township area 
of Cape Town. Though the sample was small (n=59), I was able to review three years of clinical 
and utilisation data. 
The results reported here serve as the basis for several policy recommendations and 
suggestions for further research. I hope these findings and recommendations prove helpful to 
local health policy-makers. Further, I hope that this document is informative for current and 
future researchers working in this critical area of health policy. 
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II. OBJECTIVES 
Given the need among health planners for cost data relating to HIV inpatient care, I 
endeavoured to: 
(1) describe patterns of presenting illnesses; 
(2) estimate duration of survival from time of presentation; 
(3) quantify costs of inpatient care; and 
(4) identify areas of cost-containment in care provision 
for HIV -positive patients who seek care and are admitted to township-area secondary hospitals. 
These patients would reflect the characteristics of those who are admitted to secondary 
hospital facilities in township areas in the Western Cape. They would presumably be in 
symptomatic or late-stage HIV disease (WHO stages 3 or 4) in order to be admitted.· Further, 
they would be experiencing an acute illness episode, making them more ill than others even 
within their respective disease stage. Also, because of the prohibitively high cost of HIV 
therapies, these patients would also be antiretroviral-drug naive. As a consequence of these 
factors, their costs of care may be quite different than for other HIV -infected individuals . 
• HIY -infected individuals are classified according to WHO.recognised clinical staging criteria. Stages 1 and 2 are 
relatively early stages of HN ·disease, while stage 3 indicates symptomatic disease and stage 4 denotes an AIDS· 
defining condition. 
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III. LITERATURE REVIEW 
Background 
A. Clinical literature 
The local HIV / AIDS epidemic is well characterised. Research by van Harmelen et al 
(1996) suggest that the "epidemic" is actually two distinct patterns, one sUbtype-B epidemic 
among men who have sex with men and a separate subtype-C epidemic among black 
heterosexuals.I.2 This evidence suggests that, unlike in the industrialised world, no bisexual or 
injection drug-use "bridge" existed in South Africa. 
The natural history of the local epidemic has also been analysed extensively. HIV-
infection is no more virulent here than in industrialized countries. For instance, HIV -infected 
individuals here with access to medical care exhibit a median survival comparable to that seen in 
the industrialised world prior to the advent of antiretroviral therapies in the early to mid-1990's.3.4 
However, differences clearly exist; in particular, the HIV epidemic in the Western Cape occurs 
within and alongside a pre-existing local epidemic of tuberculosis.5•9 Further, the type and 
frequency of AIDS-related opportunistic infections differs slightly from that seen elsewhere. 10 
B. Economic literature 
Several critical studies on the economic implications of HIV / AIDS in South Africa are 
contained in the volume edited by Broomberg et al. II These analyses look at the macroeconomic 
impact of HIV, and broadly concluded that the epidemic will have only a peripheral effect on 
GDP performance. They also summarise the mechanics of the popular Doyle model, which uses 
~ 
an actuarial approach to project the groWth of the epidemic in different areas of the country. This 
work was the principal existing source of scholarly information regarding HIV and the South 
African economy at the time ofthis review. 
C. Health services research 
There is a paucity of health economic research related to specific conditions or treatment 
modalities (including those for HIV) within the South Africa health system. Several authors 
report the net benefits (costs) of an interventionl2•14 or the conditions under which the intervention 
in question would prove feasible. 15•16 Other studies report the costs of a particular intervention or 
Haile B, The Costs of Adult Inpatient Care for HIV Disease at OF Jooste Hospital Page 8 
medical condition!7-23 or compare the gross or net benefits (costs) of two or more intervention 
strategies.24-27 None of these studies, however, allows us to assess whether the interventions were 
"efficient" health investments in tenns of the cost per life year gained, cost per disability-adjusted 
life year (DALY), or cost per quality-adjusted life year (QAL V). 
A few local studies do quantify and report a cost per life year (or DAL Y or QAL Y). 
Marik et al (1993) report that the cost per life year gained for intensive care at Baragwanath in 
1990 approximated R625, though their calculation is difficult to validate.28 Malan et al (1992) 
provide a more verifiable estimate of R344 per QAL Y for neonatal care at Groote Schuur in 
1990.29 Perhaps the most the most sophisticated analysis is by Soderlund et al (1998); they use a 
mathematical model to estimate a RI24 cost per life year gained for formula feeding interventions 
for HIV -positive mothers and a net savings for two alternative antiretroviral regimens for the 
prevention ofHIV-vertical transmission.30 Wilkinson et al (1999) also use a mathematical model 
to analyse the cost-effectiveness of mother-to-child transmission interventions; they calculate a 
cost per DALY ofR27, which becomes cost saving under more optimistic assumptions of care 
costs.3! Only one of these analyses above considered an intervention for adult patients, and its 
veracity cannot be established from the data reported. 
Unlike the literature froin Europe, North America, and Australia, no South African 
researchers have evaluated interventions and reported their findings for chronic diseases such as 
diabetes mellitus, hypertension, renal failure, etc. These types of analyses are perhaps most 
appropriate for comparing the cost-effectiveness of clinical interventions in adult populations. 
In terms of HIV -specific analyses, the number of studies is exceedingly small. The HIV 
cost-effectiveness literature consists of to the two studies of interventions for preventing mother-
to-child transmission (noted above). Further, the cost-of-care literature is limited to four 
studies.!7-20 Of these studies, the most ~portant are those by Kinghorn et al (1996) and Karstaedt 
et al (1996), both of whom analysed data from Baragwanath Hospital, a tertiary care facility, in 
Johannesburg. These studies will be detailed further below and in the Discussion section. 
Formal literature survey 
A. Methods 
I formally reviewed fonnal HIV patient cost and utilisation studies from South Africa and 
the United States conducted and/or published duringI989-1997. In this summary, I noted the 
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methods employed and the choice of outcomes in each study. These findings were used to 
develop the protocol for my research at GF Jooste. 
My inclusion criteria for the formal literature review were straightforward. First, studies 
must have reported either a: 
• cost-of-care outcome (e.g., cost per patient day, cost per patient month) or 
• utilisation measure of interest (e.g., inpatient admissions or number of ambulatory visits 
per year). 
Second, the sample populations had to be HIV -positive. Both published and unpublished data 
were included for review. Given my familiarity with the U.S. health care system, I narrowed the 
literature search to only those studies conducted in the U.S. or South Africa. On these bases, 
twelve studies from the U.S. and four from South Africa were reviewed (see summary table 
included as Appendix A). 11-20,32-41 (review includes unpublished data from Medi-Cal program 
(1996) and Moore (1996)) 
B. U.S. Results 
Virtually all of the U.S. studies were retrospective analyses of patient charts, hospital 
files, and institutional databases. Most studies reported a cost per patient month (or per patient 
year). This achievement is presumably linked to the availability of high-quality follow-up data. 
One study had a particularly clever approach to circumvent this problem: Hellinger (1994) 
totalled costs in the last three months of life. 
The definitions of "RN disease" and "AIDS" differed across the U.S. studies. Early 
studies relied on the 1987 U.S. Centers for Disease Control (CDC) definition of AIDS and AIDS-
Related Complex (ARC). However, due to subsequent research advances in clinical immunology 
and retrovirology. the CDC formally ~hanged its definition of AIDS in 1992 from a set of 
clinically based criteria to one defined by laboratory surrogate markers (Le., CD4 counts). 
Several authors attempted to mould their fmdings to the new lab-based categories, though the 
continued use of clinical descriptors (e.g. "asymptomatic" or "AIDS by 1987 definition'') were 
common. These different categorisations make comparisons across studies more difficult. 
The U.S. researchers generally used one of two approaches to estimate costs. In the first 
method, researchers used an entire patient database to estimate a vector of costs for individual 
services; this vector was then multiplied by an utilisation estimate generated from a survey of 
mV-positive individuals. Examples of this approach include Andrulius et al (1992). Hellinger 
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(1992), and Hellinger et al (1994). The second method involved simply used billing information 
on individual patients to estimate total costs. Examples of this "accounting" approach include 
Reitmeijer (1993), Moore and Chaisson (1996), Moss et al (1992). 
C. South Africa results 
In South Africa, the clinical literature presents both clinical and lab-based immunological 
characteristics of the local population. However, the categorization in the formal cost literature is 
limited to WHO clinical staging. This method is perhaps more appropriate given the resource 
constraints, which preclude the widespread and consistent use of expensive immunological tests. 
The costing approach differed slightly as well. Both the Kinghorn et al (1996) and 
Karstaedt et al (1996) used vectors of cost estimates derived from other sources (e.g., SAIMR 
tariffs for laboratory costs), but they also conducted a costing exercise to determine the unit cost 
of radiological services, etc. This approach is required (1) if cost-center accounting is not 
regularly used and (2) if plausible cost estimates for specific services are not available. These 
two conditions hold true for the state health care system, both at the time of Kinghorn's and 
Karstaedt's research and now. 
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IV. METHODS 
Patient Sample 
All sample data was collected from GF Jooste (GFJ) Hospital. The GFJ staff routinely 
collects statistics about patients living with HIV/AIDS. The Infection Control Sister there 
records the name, folder number, and relevant demographic data for all HIV -positive patients 
admitted to one of the inpatient wards. Such patients may be known to be HIV -positive prior to 
their admission or have a positive HIV -result while in hospital. Collectively, these patients 
constitute the popUlation from which I constructed my sample. 
I chose 1997 as the sample year as this gave sufficient time for data follow-up. Also, the 
hospital only opened in mid-1996; consequently, I felt that some delay was necessary in order to 
allow hospital data and clinical systems to be fully functional prior to the sample period. 
During 1997, the Infection Control Sister recorded 294 entries for HIV-positive inpatients. 
In order to eliminate duplicate entries, I sorted the data by surname, first name, and folder 
number. I found 23 cases where patients had been recorded more than once. 
From the 271 unduplicated inpatients recorded as HIV -positive in the Infection Control 
Log, I randomly selected 72 patient charts in order to retrospectively abstract inpatient 
utilisation.t Of these, five patients lacked HIV-test results and their chart notes made no mention 
of known HIV -status. Two additional patients were seen in the Casualty Department but were 
not admitted to an inpatient ward. One other patient had cryptococcal meningitis but had a 
negative HIV -antibody test result. Thus, our research team abstracted the inpatient utilisation for 
the remaining 64 patients for the period from August 1996f to August 1999.§ 
While abstracting the patient records for these 64 inpatients, we found one patient at stage 
~ 
1 and three patients at stage 2. In addition, we found one patient at stage 3 who was a participant 
in an antiretroviral clinical trial. Though we abstracted data on these five patients, they were 
excluded from the analysis. Therefore, the final patient sample detailed below includes some 59 
HIV -positive inpatients in stages 3 or 4 of disease. 
t To randomly select patients, I used the Excel Random Number Generator to generate a number between 0 and 1 for 
each patient. Using these numbers as the reference, I then sorted the patients in ascending order and chose the fIrst 
72. The size of the sample reflected the number of patients for which we could abstract sufficient data given our 
time constraints and limited resources. , 
t Only one oftheopatients in this sample was hospitalised during 1996 (the patient was admitted in November); 
therefore, the "start-up" effects during mid-1996 likely generated very little bias in the data. 
§ One patient was only diagnosed as HIV -positive at their second admission. Given that the fIrst hospitalisation was 
less than a week earlier, I included the first hospitalisation as part of the study. 
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Antiretroviral use 
Researchers in North America and Europe have demonstrated that anti-retroviral use (the 
so-called dual- and triple-"cocktail" therapies) can reduce morbidity and mortality.42-44 
Subsequently, researchers showed that these drugs dramatically alter utilisation patterns and costs 
of care for HIV disease.36,45-48 For these reasons, it is important to ensure that the sample data 
does not combine patients who were accessing anti-retroviral therapies with those who were not. 
The patients included in this sample are highly likely to be anti-retroviral naive. The 
Sister in Charge at the Clinical Research Centre of Somerset Hospital reviewed the list of patients 
in the sample to determine whether any were participants in the Centre's clinical trials. Only one 
patient was a participant in a clinical triar· and, as noted in the "Patient Sample" section above, 
data was abstracted for this patient but later excluded from the analysis. It is possible that some 
patients in our sample accessed antiretroviral therapy through private providers or other clinical 
trials, though the geography and economic status of the patient population makes this a remote 
possibility. 
Data Collection 
A research team of four abstractors used a customised chart abstraction form to capture 
the GFJ inpatient utilisation data.tt I developed this chart abstraction instrument in consultation 
with Dr. James G. Kahn, Associate Professor at the University of California, San Francisco; Dr. 
Norman Maharaj, Superintendent of GF Jooste; and Dr. Yumna Williams, Medical Officer in 
Ward 2 of GF Jooste. This instrument enabled abstractors to collect data on patient 
demographics, patient admission data, laboratory tests, diagnostic and treatment procedures, 
radiology, and medications. Dr. Williams and I piloted the instrument at GF Jooste in May to 
July, 1998 by abstracting the data fipm five patient folders and revising the instrument as 
appropriate. The final version of the instrument used for all data collection is included as 
Appendix B. 
Data collection took place between July 1998 and September 1999. In the last month of 
data collection, we reviewed all files of patients surviving after January 1, 1998 to ensure that we 
captured any documented utilisation in the time since we began abstracting data . 
•• The patient's clinical trial participation was also noted in the GFJ folder. 
tt The abstractors, Dr Y Williams, F McGill, G Meijer, and N Schrueder, were all final-year medical students or 
Medical Officers. Dr. Williams and Ms. McGill captured data for 70% and 21 % of the patients, respectively. 
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After entering all data into an Excel spreadsheet, I reviewed each chart abstraction and 
noted any irregularities, unusual or large quantity utilisation, and other abnonnalities or outlying 
results. Dr. Williams answered any questions about the chart abstractions if the original files did 
not provide sufficient infonnation. We consulted with specialist physicians in HIV medicine at 
Somerset Hospital and other hospitals with any unresolved questions. 
Hospitalisations and Length of Stay 
Descriptive statistics about patient admission were principally gathered from the patient's 
chart. As often as possible, I coded the inpatient admission and discharge dates as they are 
recorded in the patient's file. These dates occasionally differed with the computerised GFJ 
admissions records by one or (rarely) two days, which may be the result of late-night admissions 
or delay in processing files within the CasualtylRecords Department. When the date of 
admission or discharge was unclear in the patient notes, I relied on the computerised records. 
To check the number of admissions, I compared the data from the inpatient notes with the 
computerised admission records. In several cases, a patient was discharged and shortly thereafter 
readmitted, but the patient notes recorded only a single hospitalisation. In such cases, I relied on 
the computerised records to assess the total number of hospitalisations if no further infonnation 
was available. Also, the computerised admission records in several instances suggest that 
patients were admitted only as Casualty patients. Where inpatient discharge summaries, etc. 
existed in the patient file, I assumed that the patient had been admitted to the ward as an inpatient. 
I calculated length of stay (LOS) by subtracting the date of discharge from the date of 
admission. For example, a patient admitted on 04-Jan-98 and discharged on 07-Jan-98 had a 
LOS of three days. In cases of same-day admission and discharge, I set the LOS equal to one. 
Diagnoses and WHO Staging 
All patients in this study either tested positive for HIV -antibodies at GFJ or were known 
by the clinical staff to be HIV-positive. The frequency of HI V-tests and confirmatory assays was 
recorded for each patient in the sample. If a patient had a single HIV -test result, I assumed the 
test used was a Rapid Screen assay; this assumption is consistent with the HIV -testing protocol at 
GFJ during the study period. 
Using the World Health Organisation's (WHO's) Clinical Staging Criteria, 48 the ,. 
abstractors detennined the clinical stage of the patients for each hospitalisation. Additionally, the 
abstractors reported the discharge diagnoses for each patient based on the lab results, chart notes, 
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and discharge summaries in the folder. If the reviewer or abstractors queried the clinical staging 
or diagnoses, we consulted with local HIV-specialist physicians to confinn the abstractors' initial 
conclusions. 
The coding of tuberculosis in this study reflects the uncertainty surrounding tuberculosis 
diagnoses at GFJ. I coded cases as "TB confinned" if the patient had least one AFB- or culture-
positive result. I coded cases as "TB (given Tx)" for patients who were given treatment but who 
lacked a documented laboratory diagnoses. Finally, I coded cases as "TB suspected" if the chart 
notes mentioned suspicion of tuberculosis or if the patient was referred to a local TB clinic. None 
ofthese latter cases were prescribed anti-TB medications prior to the discharge from GFJ. 
For purposes of this study, I considered a single laboratory-positive result as a confinned 
TB diagnosis. However, this practice differs from WHO guidelines, which require confinnation 
of TB from a second AFB- or culture-positive result. For costing exercises in a TB-endemic 
area, however, the use of a single result probably introduces little bias (personal communication, 
Dr Robin Wood, 3/9/99). Further, in this setting, GFJ clinicians may base their treatment 
decisions on a single AFB- or culture- positive result. For these reasons, a single laboratory-
positive result seemed sufficient for a non-clinical analysis. 
Survival and Follow-Up Data 
Dates of death and other follow-up data were collected from the GFJ patient folders, the 
City of Cape Town Department of Health, the City of Tygerburg Department of Health, the Red 
Cross Society's HIV/AIDS Home-Based Care Program, St. Luke's Hospice, and the Missionaries 
of Charity (Sisters of Mercy) Hospice. In some cases, the first names of patients were recorded or 
spelled differently in the patient/client databases than in the GFJ folder. If the age, sex, township 
were the same and if the patient's date of death was after date of last GFJ discharge, I assumed 
that the patient's identity was the same.h 
The data were used to construct Kaplan-Meier "survival" tables and confidence intervals§§ 
for patients in stages 3 and 4. To evaluate the sensitivity of my estimates to differences in staging 
practices, I used four different coding methods and compared the results. If these methods 
generate consistent estimates, then I can be more confident that minor variations in clinical 
U Interestingly, the medical examiner/district surgeon listed AIDS, tuberculosis, or "acute pulmonary heart disease" 
as the cause of death for most patients in question. 
§§ Standard Kaplan-Meier tables were constructed, and 95% confidence intervals were estimated using the method 
reported by Hosmer and Lemishow (1999). 
Haile B, The Costs of Adult Inpatient Care for HIV Disease at GF Jooste Hospital Page 15 
staging among doctors have little impact on the survival estimate for each disease stage. I used 
the following coding rules: 
Method A: Assumes that staging is correct; includes censored observations 
Method B: Assumes that staging is correct; excludes patients lost to follow-up and censored 
Method C: Assumes that stage 3 patients who die within two weeks of discharge were 
actually stage 4 at their last hospitalisation; includes censored observations 
Method D: Assesses time to death of patients initially presenting at stage 3 (rather than time to 
progression to stage 4 or death) 
A comparison of the results should therefore indicate the effect of minor variations in 
retrospective coding on median time to progression or death for patients in each stage. 
Inpatient Costs 
In my approach to costing, I implicitly assumed that HIV -infected inpatients have the 
same intensity of nursing and clinician utilisation as other ward inpatients at GFJ. Unfortunately, 
it is not possible to validate this assumption in practice. Given the volume of patients, nurses and 
treating clinicians would not be able (nor willing) to maintain an accurate log recording time 
spent with each patient. Further, it may not be possible to correlate the patient names and 
clinician time in such a log with HIV -test results. 
Consequently, I calculated two types of costs in order to estimate a cost per inpatient day 
for HIV -positive inpatients. First, I calculated the general recurrent cost per inpatient day at GFJ 
for 1997. These costs exclude those for which patient-specific data exists (e.g., laboratory tests, 
radiology, diagnostic and treatment procedures, and medications). Second, I calculated a cost per 
inpatient day for utilisation that is patient-specific. 
A. General Recurrent Cost per Inpatient Day 
To calculate general patient costs, I modified the standard fonnula used to compute 
estimated daily average costs (EDAC). The standard fonnula presently used in the Provincial 
Administration is: 
net 
EDAC = outl3 + in 
net = net expenditure 
out = number of outpatient and casualty visits 
in = number of inpatient days 
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I made two changes to the formula and inputs: 
(1) To exclude patient-specific and capital costs, I subtracted all costs for medications, specific 
medical equipment for procedures, laboratory tests, and capital expenditures from "net." 
These costs were reported in a statement of 1996/97 GFJ expenditures.··· 
(2) To more accurately reflect costs of outpatient and casualty visits, I increased the coefficient 
of "out" to 0.43 from 0.33. This is consistent with estimates reported in recent research.49 
With this modified formula, I estimated the general costs per inpatient day. 
B. Patient-Specific Costs 
To calculate patient-specific expenditures, I multiplied the utilisation data captured in the 
retrospective chart review by an array of unit costs. This array was generated from the following 
data sources: 
(a) Laboratory costs were from the South African Institute of Medical Research's (SAIMR) 
1996/97 tariff; ttt 
(b) Costs for radiology and diagnostic and treatment procedures reflect the 1996 Scale of 
Benefits (Sc/B) rates reported by the Medical Association of South Africa;m 
(c) The costs of stores and fluids§§§ were 1998/99 provincial tender prices, which were 
appropriately adjusted for inflation; and 
(d) The costs of medications were 1996/97 provincial depot catalog price; for drugs not "on 
code," the 1996/97 provincial tender price was used. 
When stores were required for drug delivery (e.g., syringes, nebuliser masks, etc.), they 
are included in the cost of the medication. In the case of IV drips, however, multiple drugs and 
fluids can be dispensed with a single pump, tube, and needle; the IV drip is therefore considered 
separately from any specific medication. 
In several instances, the drug dose and/or method of delivery recorded in the abstractions 
was implausible. A physician reviewed all reported drugs and dosages; in clear cases of error, the 
reviewer suggested the dose most likely to have been prescribed and dispensed. In other cases, 
the patient chart was reviewed for additional information. Specific notes in this regard are found 
in1he Unit Cost Table in Appendix C . 
••• M. Blecher at the Department of Health provided this "level-four" disaggregated accounting statement. 
ttt SAIMR 1996/97 tariff schedule reported rates for September 1996 to September 1997. 
W ScIB rates for 1996 were used as per suggestion by D MacIntyre as these likely represented costs for diagnostic 
and treatment procedures within the public sector in 1997. 
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Physician Review 
Once the data coding, analyses, and summary were complete, I conducted two structured 
interviews with HIV -specialist physicians. They reviewed each of the data tables presented 
below, particularly the discharge diagnoses and the expenditure analysis. With the expenditure 
analysis, they provided suggestions as to how resources may be better targeted. Further, they 
suggested areas in which spending can be reduced with minimal effect on the clinical 
management of patients. 
m Stores and fluids include needles, syringes, bandages, IV's, rehydration fluid bags, blood, etc. 
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v. RESULTS 
Descriptive Statistics 
The original patient sample (n=72) decreased as we eliminated those persons who did not 
have any details of HIV -status, who were not in stage 3 or 4 disease, or who were on an 
antiretroviral clinical trial. The resulting sample (n=59) was subdivided into three exclusive 
categories of hospitalisations: 
(a) those occurring in stage 3; 
(b) those occurring in stage 4 among patients who initially presented at stage 4; 
(c) those occurring in stage 4 among patients who initially presented at stage 3. 
Note that patients in (a) and (b) are mutually exclusive, while (a) and (c) necessarily overlap. 
Initially WHO Initially WHO 
Stage 3 Stage 4 
Sample size 35 24 
% Female 62.9% 62.5% 
Mean age 34 33 
Total hospitalisatlons 48 29 
Total Inpatient Days 251.0 116.0 
Mean LOS 5.2 4.0 
95% Cis (0.0,14.0) (0.0,8.8) 
Transfer to 








The descriptive statistics from this sample are presented in Table 1. The 35 patients who 
initially presented in stage 3 had 48 hospitalisations before progressing to stage 4, death, or being 
lost to follow-up. Nine patients who initially presented in stage 3 were subsequently hospitalised 
as stage 4. For hospitaIisations in staKe 3, the mean length of stay (LOS) of 5.2 days is slightly 
higher, though not statistically different, than for hospitalisations in other categories. The mean 
patient age and the proportion of female patients were consistent across categories. 
Extrapolating from the sample, the total of 271-recorded HIV-positive inpatients likely 
had about 400 admissions with some 1,800 inpatient days during stages 3 and 4 (data not shown). 
These estimates represent 1.5% of total admissions and 2.0% of inpatient days at OF] for FY 
1997/98 and 1998/99 combined. 
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New HIVand T8 Diagnoses 
Because HIV and TB are overlapping epidemics in the Western Cape, I jointly report the 
new HIV and TB diagnoses among these patients. The inter-relationship between these local 
epidemics is explored elsewhere,50 though it is important to note that TB prevalence among HIV-
infected individuals (particularly Black African patients) is quite high. 
Most of the patients in this sample (79.6%) received an HIV diagnosis while at GFJ. The 
majority of diagnoses were made with a single Rapid Screen assay, though most of these were 
sent to the VCT Virology Laboratory for two confirmatory ELISA tests.···· In a few instances, 
more than one Rapid Screen test was documented in the patient file; a single ELISA confirmatory 
test was often done following the second Rapid Screen test. 
Table 2: New Hf\r 
Diagnosis 
Initially WHO Initially WHO Transfer to 
Stage 3 Stage 4 Stage 4 from 3 
One positive Rapid Screen 1 23 16 0 
Two or more positive tests2 5 2 0 
Outside of GF Jooste 7 6 0 
1 The first Rapid Saeen was often automatically followed by two ELISA tests. 
2 The serond test was most often a Rapid Screen, followed a single conflmatory ELISA test 
A high proportion of these patients received a tuberculosis diagnosis while in hospital. 
Well over half (65.7%) of stage 3 patients either had at least one AFB- or culture-positive result 
and/or were given anti-TB medications. The latter were presumably given medication because of 
a previous diagnosis outside of GF Jooste or their TB diagnosis was not properly documented in 
the patient file. Tuberculosis prevalence fell in later disease stages, though there may have been 
undiagnosed cases among moribund/terminal patients. 
Table 3:T8 Diagnoses and Prevalence (nu~be~Ofpatients) 
Diagnosis 
One AFB+ or culture+ result 1 
No documented result, given Tx2 
Percent of total patients 
Initially WHO Initially WHO 







lOne patient again tested positive for TB six months after initial test. 
2 Especially with cases diagnosed outside GFJ; independent of confirmed cases . 
Transfer to 




•••• The GFJ administration halted this practice in 1997-98; the GFJ laboratory now recommends that the doctor send 
a second specimen to OCT for a confIrmatory ELISA test if a patient is Rapid Screen-positive. 
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Two particular issues are noteworthy. First, these data confinn the high prevalence of TB 
among HIV -infected inpatients. Second, these data suggest that primary health care providers 
may not have detected and/or treated a high proportion of these cases prior to the inpatient 
admission. Given the public health implications regarding tuberculosis co-infection, these 
findings are cause for concern. 
Use of Co-trimoxazo/e 
Recent reports suggest that co-trimoxazole use in stage 3 patients confers a significant 
survival benefit.51 ,s2 As a result, the forthcoming HN Clinical Guidelines recommends co-
trimoxazole prophylaxis for all patients in stages 3 and 4. Given the efficacy of this relatively 
inexpensive drug, we recorded its utilisation (including both treatment and prophylactic doses) 
among the patients in the sample. 
The use of co-trimoxazole was surprisingly low. Only about one-fifth of stage 3 
admissions included any dose. Roughly the same proportion in stage 4 were prescribed co-
trimoxazole, though the high in-hospital mortality among patients initially presenting at stage 4 
may explain the low use. The number of patients for analysis, however, remains quite small. 
Table 4: Co.trimoxazoleuse:'·siratified~bYTij';iliti.\i~~tifij6SPit8li 
Diagnosis 
Initially WHO Initially WHO Transfer to 
Stage 3 Stage 4 Stage 4 from 3 
TB admissions wI co-trimoxazole Tx1 5 2 
TB admissions2 24 10 
Percent of hospitalisations 20.8% 20.0% 
Non-TB admissions wI co-trimoxazole Tx 6 3 
Non-TB admlssions3 24 19 
Percent of hospitalisations 25.0% 15.8% 
1 Co-b1moxazole, any dose. 
2 Admissions in which TB was either a primary or secondary diagnosis; excludes suspected TB cases. 







Two other interesting results warrant mention. First, co-trimoxazole use was largely 
independent of continned TB status. Second, co-trimoxazole use was much higher in admissions 
among those who initially presented at stage 3 and who had progressed to stage 4 (Le., those who 
were already receiving care). Even so, co-trimoxazole appears to be under-utilised, particularly 
given its effectiveness and affordability. 
Haile B, The Costs of Adult Inpatient Care for HIV Disease at GF Jooste Hospital Page 21 
Patient Diagnoses at Discharge 
Discharge diagnoses for these patients are reported in Table 5. Given the high rate of 
stage 4 patient mortality in hospital, these figures may underestimate the actual frequencies as 
there may have been undiagnosed cases among moribund/terminal patients. 
Diagnoses 
Initially WHO Initially WHO Transfer to 
Stage 3 Stage 4 Stage 4 from 3 
HIV-Related, non-Ol 
Candida, oral/vaginal (given TX)1 7 14.6% 8 27.6% 7 26.9% 
Candida, oral/vaginal (noted) 4 8.3% 2 6.9% 3 11.5% 
Gastrointestinal complaints2 10 20.8% 7 24.1% 17 65.4% 
PTB (confirmed or given Tx) 24 50.0% 9 31.0% 3 11.5% 
PTB suspected 5 10.4% 5 17.2% 1 3.8% 
Respiratory complaints 8 16.7% 2 6.9% 5 19.2% 
Opportunistic Infections 
Candida, oesophageal nla 1 3.4% 0 0.0% 
Disseminated TB (given Tx) nla 1 3.4% 0 0.0% 
Disseminated TB suspected nla 2 6.9% 0 0.0% 
Kaposi's sarcoma nla 1 3.4% 0 0.0% 
Meningitic illness suspected nla 7 24.1% 0 0.0% 
Other neurological conditions nla 4 13.8% 1 3.8% 
Wasting nla 1 3.4% 0 0.0% 
Non-HIV Related 
Cardiac: CFO/CMO 0 0.0% 0 0.0% 4 15.4% 
Diabetes 1 2.1% 0 0.0% 4 15.4% 
PID (grade I, II) 1 2.1% 2 6.9% 0 0.0% 
Renal impairment/failure 0 0.0% 2 6.9% 2 7.7% 
Other diagnoses2 8 16.7% 5 17.2% 6 23.1% 
Teminal: no investigations 0 0.0% 2 6.9% 1 3.8% 
1 Diagnosis not doCl.ll1eflted in doctors notes, etc., Iho~h use of topical anll-fu1ga1s consistent Vv'ith candida. 
2 No orgarism Isolated. 
3 Treatment modalties for these conditions vary more widely than for respiratory and gastrointestinal complaints. 
4 Please refer to Appendix D tor a detailed break-down of ·Other diagnoses.· 
Note: columns dO not sum because some patients have multiple diagno~. 
Tuberculosis was common in all categories of patient hospitalisations. Pulmonary 
tuberculosis was confirmed and/or treated in 50.0% of stage 3 hospitalisations, and tuberculosis 
(pulmonary and disseminated) was reported in 31.0% of all hospitalisations among those who 
initially prese:r:tted in stage 4. Other respiratory complaints (particularly pneumonias) were also 
widespread, especially in stage 3 hospitalisations. 
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The frequency of gastrointestinal complaints were also quite high. Over one-fifth of stage 
3 hospitalisations involved gastrointestinal problems (diarrhoea, vomiting, dysentery, etc.); the 
frequency increased dramatically in later-stage admissions. Few of the patient notes mention the 
isolation of any organism (e.g., cryptosporidiosis, etc.), though this aspect was not investigated 
thoroughly in this study. 
The occurrence of suspected meningitic illnesses and other neurological conditions was 
high as well. These conditions were often the presenting illnesses for many patients in stage 4 
disease. In contrast, oesophageal candida, Kaposi's sarcoma, and wasting were quite rare. 
Oral and/or vaginal candida (or "thrush'') were documented in less than 10% of all 
hospitalisations. This finding is surprising given the anecdotal reports of higher prevalence in 
similar facilities. However, the frequency of candida in this sample was likely much higher than 
was reported in the patient files. Judging from the prescriptions for nystatin, clotrimazole, and 
amphotericin B medications (all of which are used to treat candidiasis), it appears that oral and/or 
vaginal candida were likely present in a total of 22.9% of stage 3 hospitalisations and more than 
35% in stage 4 admissions. While reasons for such under-reporting remain unclear, candida may 
have been secondary diagnoses for these patients and as such were simply not documented in the 
chart notes and discharge summaries. 
Patient Survival 
The Kaplan-Meier survival analyses generated some of the more interesting results in this 
study. Patients who initially presented in stage 4 survived a median of only 20 days. The narrow 
confidence intervals suggest a reasonable degree of certainty about this estimate. Indeed, 
regardless of the method used to estimate their survival, the patients who initially present at stage 
4 lived for only a brief period of about ~o to three weeks. 
There is less certainty, however, about the survival of patients who present in stage 3. 
They spent a median of 273 days in stage 3 before progressing to stage 4 or death. Of the nine 
patients that progress to stage 4, they survive a median of 59 days in that stage. Overall, patients 
initially presenting in stage 3 survive for a median of 401 days. However, each of these estimates 
has quite large confidence intervals, indicating the high level of uncertainty around the median 
estimate. For these reasons, one has much less confidence in the point estimates for median 
survival of patients who initially present in stage 3 and for those who transfer to stage 4. 
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Table 6: K-M Median Survival (days) 
Initially WHO Initially WHO Transfer to 
Stage 3 Stage 4 Stage 4 from 3 
Method A 273 20 59 
95%CI (15,531 ) (4,36) (0*,210) 
n 35 24 9 
Method B 118 18 7 
95%CI (6,230) (12,24) (0*,85) 
Method C 394 12 10 
95%CI (212.576) (1.24) (0*,71) 
Method D 401 
95%CI (0*,898) 
n 35 
* Negative numbers were excluded and lower bound set to O. 
Method A: Assuming that staging is c:orrect; includes censored observations 
Method B: Assuming that staging is correct; exdudes those lost to follow-up 
and censored 
Method C: Assuming that those in stage 3 who die within two weeks of 
discharge were actually stage 4; indudes censored observations 
Method 0: Survival of those initially in stage 3 
The different coding methods yielded consistent median survival estimates only for 
patients who initially present in stage 4. For other stages, the use of different rules for coding 
WHO stage yielded considerably variability in the respective median survival estimates. For 
example, if I exclude all inpatients classified as stage 3 and who die within two weeks of 
hospitalisation (Method C), the median survival for stage 3 inpatients increases from 273 to 394 
days. Thus, it appears that minor variations in coding do have an impact in survival estimations 
for stage 3 and other patients. 
Patient Transfers/Referrals 
Many of the patients who present at GF Jooste are eventually transferred or referred to 
other health centres. Of stage 3 discharges, 16.7% involved a patient transfer to Brooklyn Chest 
Hospital (BCH), an inpatient TB treatment facility. Another 14.6% involved a transfer or referral 
to Groote Schuur Hospital (GSH) for specialist care or follow-up. Of the seven stage 3 GSH 
transfers, three were for CT scans and two were for PCP or other pneumonias; of the eight GSH 
transfers among patients initially presenting at stage 4, three were for suspected meningitic illness 
'. 
and two were for other neurological conditions/procedures (data not shown). 
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Effective utilisation of primary care-level facilities is an important goal within the state 
health system, and I sought to assess the actual use of local clinics as referrals sites. While 
referrals to local day hospitals or clinics may not be consistently documented by clinicians, those 
to local TB clinics require the completion of a separate form (a copy of which is retained in the 
patient's file). We were therefore able to record the number of documented referrals to these TB 
specialty clinics. 
':"~, ":i:~~ ,' _ _ .,!,'~;:J/i , ... ; ;-:: <." 
TabJe~7:: Patient Transfers/Referrals. 
Transf to BCH (cases)3 
Transf/Ref to GSH 
Referred to TB Clinic4 
1 Percent of hospitalisations 
Initially WHO 
Stage 3 
Cases Percent 1 LOS2 
8 16.7%3 8.8 
7 14.6% 2.4 
9 18.8% 6.3 
2 GFJ mean length of stay (LOS) reported here. 
Initially WHO 
Stage 4 
Cases Percent LOS 
1 3.4% * 
8 27.6% 4.5 
3 10.3% * 
Transfer to 
Stage 4 from 3 








3 In stage 3, two patients were each transferred to BSH on two separate occassions, separated by at least six months. 
4 In stage 3, one patient was referred to local TB clinic on two separate occasslons, separated by at least 12 months. 
• No means reported if number of cases <4 
GF Jooste doctors recorded twelve referrals to local TB clinics. Of these, nine had 
confirmed TB or were given anti-TB medication at GF Jooste (data not shown). This figure 
could underestimate total referrals to local TB clinics as some doctors may not retain a copy of 
the referral form in the patient file or note the referral in the patient's chart. Given that 15 cases 
of TB were newly diagnosed at GFJ, these data suggest that local TB clinics may be adequately 
utilised by clinicians for follow-up management ofTB patients. 
Patient Mortality 
~ 
Patient mortality was quite high among those who initially presented in stage 4 disease. 
In over one-half of stage 4 admissions, the patient died in hospital or within two weeks of 
discharge, which compares to only 16.9% in stage 3 hospitalisations. A large majority of those 
who died in hospital or within two weeks of discharge (6 out of 8 deaths among those initially 
presenting stage 3 deaths and 10 out of 15 deaths among those initially presenting in stage 4) died 
during or following their first hospitalisation. 
In terms of discharge diagnoses, there was no discernible trend among the patients who 
died in hospital or within two weeks of discharge. Of the 15 deaths among patients who initially 
presented at stage 4, four were associated with meningitis or other neurological conditions. Yet, 
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the prognosis of patients with suspected meningitis was not universally poor; contrary to 
expectations, only two of the seven total suspected meningitis cases died in hospital or within two 
weeks of discharge, and only one suspected case of meningitis was lost to follow-up. Thus, the 
data from this small patient sample do not support any diagnostic or prognostic clues that help 
distinguish terminal/moribund patients from those in the same disease stage who had better 
prospects for survival. 
Initially WHO 
Stage 3 
Cases Percent 1 LOs2 
% Died in GFJ Hospital 
% Died <2 wks after dlc 
1 Percent of hospitallsations 
5 
3 
~ Mean length of stay (LOS) reported here . 














Stage 4 from 3 





General patients costs are presented in tables 9 and 10. Disaggregated expenditures in 
Table 9 and the patient volume reported in table 10 yield a general cost per inpatient day ofR504. 
This estimate excludes capital costs as well as patient-specific utilisation (e.g., laboratory tests, 
radiology, diagnostic and treatment procedures, and medications). 
Table 9: Gerieral Costs at GFJ 
Personnel 
Adm instrative 
Store & Livestock 
Equipment (excl Cap) 


















OPO, CAS % of INP 
GFJ General Cost/Day 







Patient-specific costs are reported in Table II. tttt The mean total cost for laboratory tests, 
radiology, diagnostic and treatment procedures, and medications per inpatient day in stage 3 is 
RI51.36. The wide confidence intervals for these estimates suggest that there is a high degree of 
variability in patient-specific costs. Interestingly, mean spending estimates for the larger 
categories of expenditures (e.g. radiology and medications) are broadly consistent between stages 
3 and 4. 
Table 11 : Patient Costs (non-hotel CostsonIY)r:~~~:~;":}: 
Transfer to 
Initially WHO Initially WHO Stage 4 from 
Stage 3 Stage 4 3 














Mean Cost per Hospltallsati 520.39 
95% CI (0.00*, 1,309.61) 
Lab Tests 258.06 
Diagnostic Procedures 8.45 
Radiology 64.78 
Medications, etc. 183.02 




























Laboratory spending is the notable exception. Approximately one-half of patient-specific 
costs in stage 3 are attributable to suc~tests, whereas laboratory costs comprised less than 40% of 
stage 4 costs. Indeed, the difference in laboratory spending between stages 3 and 4 constitutes the 
bulk of the difference in total spending per inpatient day between these categories. 
Relative to other categories, patient-specific costs decline dramatically for patients who 
progress from stage 3 to 4 and are subsequently hospitalised. Spending on diagnostics (laboratory 
tests, radiology and procedures) is much lower in this category than in others, perhaps because 
the treating clinician had a more comprehensive patient history/chart at the time of admission. 
tttt Total patient spending in each category is included as Appendix E. 
Haile B, The Costs of Adult Inpatient Care for HIV Disease at GF Jooste Hospital Page 27 
Expenditure Analysis 
In most instances, spending in different categories is principally driven by a single 
expenditure item (e.g., chest x-rays under "Radiology;" data not shown). However, the 
magnitude of spending in four sub-categories was not attributable to any single item. These sub-
categories and the main expenditure items are reported in Table 12. For example, blood gases 
made up the largest expenditure item under Lab: Chemistry; a total of R841.32 was spent for 
these tests during stage 3 hospitalisations. 













































Augmentin (PO) 452.82 
Cefuroxime (IV) 228.02 
Penicillin (IV) 178.18 
Flagyt (1 g PR) 123.50 
Oftoxacin (PO) . 109.72 
Ciproftoxacin (PO) 100.42 
Other 500.63 
"ndiiQres~(all~biRi~lis~tiohs in sa~pr~)r;); 
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It is worth highlighting a few of these findings, which are explored further in the 
Discussion section. With respect to Lab:Chemistry spending, patients typically received four 
tests upon admission (potassium, sodium, urea, and creatinine). Many patients also had 
osmolality, iron studies, and liver function tests while in hospital. Regarding Lab: Haematology 
spending, only the use of differential counts is noteworthy. Finally, in terms of pharmacy 
utilisation, antibiotics were the only component that could be further disaggregated; of particular 
interest, augmentin (a broad-spectrum antiobiotic) was used often in stage 3 patients. In the 
Discussion section, the implications of these findings will be explored. 
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VI. DISCUSSION 
Statistical Methods 
Samples of this size frequently generate large confidence intervals, and several of the 
inferences could simply be spurious correlations (statistical noise). However, a sample of this 
size may still allow one to examine several broad trends in the patient composition and attendant 
costs ofHN care at OF Jooste. These issues are explored in the following sections. 
The use of statistical asymptotic theory in this study is admittedly dubious. The sample of 
OF Jooste hospitalisations is not one of statistically independent events: some patients are 
admitted as inpatients on multiple occasions, and underlying community factors (e.g., virulent flu 
season or concentrated flu epidemics) may affect the frequency of hospitalisations. Also, the 
distribution of LOS and other observable outcomes is unlikely to be normally distributed as I 
have assumed. However, the use of asymptotics in estimating confidence intervals does help 
illustrate the large degree of uncertainty around many of the point estimates even if the intervals 
themselves are technically inaccurate. While stating the computed variance or standard errors 
would be more precise, lay decision-makers may not as readily understand their meaning. For 
these reasons, I elected to portray the degree of uncertainty around the point estimates using 
conventional asymptotics, though I acknowledge the technical weaknesses of this approach. 
Descriptive Statistics 
The confirmed HIV patient load represents a relatively low volume of .total patients 
(roughly 2%) at OF Jooste over the time period of the research. Of course, only patients with 
HN-related symptoms were tested, so the actual prevalence of HN could be higher. Even so, 
anecdotal reports suggesting that the proportion of HIV -infected inpatients in the wards may be 
40% appear exaggerated. While the proportion of hospital inpatients infected with HIV will 
inevitably rise as the epidemic matures, the low confirmed HIV patient load suggests that OF 
Jooste is still in the early stages of the HIV crisis. 
Clearly, the confirmed HIV patient volume cannot be correlated to inpatient prevalence 
with any precision. The point estimate of HIV patient volume at OF Jooste is likely to fluctuate 
considerably over time: as the tendency changes among clinicians to test patients for HN, so to 
will the estimlilte of HIV among inpatients. For this reason, year-on-year comparisons probably 
Haile B, The Costs of Adult Inpatient Care for HIV Disease at GF Jooste Hospital Page 30 
yield very little useful information. Consistent trends may be more revealing, though individual 
point estimates shall remain suspect. 
Extrapolating a community seroprevalence from the confirmed mv patient volume is 
even more problematic. Because HIV testing is largely conducted following a clinical 
(presumptive) diagnosis ofHIV-related illness at GFJ, it is perhaps more appropriate to view the 
number of HIV confirmed cases as an proxy for AIDS prevalence rather than the underlying HIV 
prevalence in the communities served by GF Jooste. 
The higher proportion of female patients (see Table 1) is likely the result of several 
factors. First, there is a biological component as the ratio of HIV in men to women in Africa 
remains about 1.0: 1.1. (Department of Health, unpublished data and Dr Gary Maartens, personal 
communication,7112/99). Second, some female patients may have previously been diagnosed as 
HIV -positive through ongoing antenatal surveillance efforts at state clinics; this factor may 
explain why females made up only 57.4% of new diagnoses at GFJ (data not shown). Third, 
females may be more likely than males to seek services from the state hospital system due to a 
variety of economic and cultural factors (e.g., higher female unemployment, free maternal-child 
health care, etc.). Given these factors, it is likely that GF Jooste will continue provide HIV-
related clinical care to a greater nUmber of women than men in the short- and medium-term. 
New HIVand 18 Diagnoses 
While very few patients apparently knew of their HIV status prior to admission, many of 
the HIV diagnoses at GFJ were initially clinical or presumptive diagnoses. This suggest that this 
sample is likely biased towards patients who are symptomatic and/or at discernibly late stages of 
HIV disease. 
Given that most of these diagnoses are new, pre- and post-test counselling issues would 
have been very important. Yet, such counselling was documented in only eight of the 46 patients 
tested at GF Jooste (data not shown). Many patients may have been counselled and the clinician, 
social worker, or counsellor may have simply not included any notes in the chart. However, it is 
likely that a number of patients received little or no counselling, particularly those patients who 
speak only Xhosa. 
The prevalence of TB among this patient sample is high (see Tables 3 and 5), which is 
consistent with our expectations given the underlying community prevalence. The patient 
population is Immune suppressed and resides in a TB-endemic area. Because of their level of 
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immune suppression, however, it is often necessary to make a clinical diagnosis of TB. m: 
Consequently, many patients appear to have been treated either without a lab-confinned TB result 
or on the basis of a single AFB- or CUlture-positive result. 
Use of Co-trimoxazo/e 
Co-trimoxazole represents one of the few feasible interventions available within the state 
medical system. It confers a significant survival benefit, lowers morbidity from a variety of 
opportunistic infections, and costs only six cents per daily-dose tablet. Noting the importance of 
this prophylactic medication, the Health Minister has consistently included it on the Essential 
Drug List as an indicated therapy in later-stage HN infection. 
Unfortunately, however, baseline use of co-trimoxazole appears to be relatively low in 
this patient population (see Table 4). Co-trimoxazole use was highest among stage 4 patients 
who had previously been hospitalised in stage 3 disease, but it was consistently low for those 
initially presenting in either stage 3 or 4. This intervention may help explain the higher median 
survival among patients who transitioned to stage 4 relative to those who initially present at stage 
4.§§§§ Further, it vaguely suggests that transitioning from stage 3 to 4 may serve as an important 
"trigger" to clinicians to prescribe preventative interventions. 
Interestingly, the use of co-trimoxazole was not related to TB status. This result is 
somewhat surprising, given that some clinicians, both local and intemationally,46.47 were 
discussing the use of the drug in co-infected patients at earlier stages of HN disease during the 
research period.····· Presumably, this discussion would have resulted in a higher proportion of 
TB-infected patients being prescribed co-trimoxazole. This was not the case as TB status did not 
seem to impact on the likelihood of co-trimoxazole use. 
These data illustrate the large magnitude of benefits could be realised as this intervention 
becomes more widely used. In order to achieve these patient gains, though, medical 
superintendents must both increase the use of co-trimoxazole in their own facilities and 
coordinate patient follow-up and maintenance therapy with day hospitals and local clinics. 
UU Tuberculosis may not be clearly evident on chest x-rays from an immune-suppressed patient, and such patients 
are often unable to produce sputum for laboratory analysis. 
§§§§ Of course, the alternative may be true: patients who survive longer may simply be more likely to receive a 
prescription co-trimoxazole . 
••••• Following published reports that appeared in early 1999, these discussions were formalised and co-trimoxazole 
is now indicated as an OI-prophylaxis for all patients in Africa co-infected with HIV and tuberculosis in addition to 
those who are at stages 3 or 4. 
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Patient Diagnoses at Discharge 
The frequency AIDS-defining opportunistic infections (OIs) observed in this sample 
roughly parallel those reported by Wood et al (1996), though their Cape Town sample was 
considerably larger. In our sample, however, pUlmonary tuberculosis was much more prevalent. 
This is partially attributable to the different patient samples, though the extent to which this 
explains the difference is not known. 
Among patients in the present study, the high frequencies of gastrointestinal complaints, 
non-TB respiratory conditions, and candidas are notable (see Table 5). Indeed, these complaints 
were reported with higher frequency than in the study by Karstaedt et al (1996) and other local 
studies. Yet, the frequency of these conditions may reflect a supply issue (Le., patient is admitted 
because treatment is available) as well as a higher frequency of these illnesses in this population. 
Further, it may reflect poor clinical management: patients return for repeated episodes or are 
referred to GF Jooste after being improperly treated at a lower-level facility. For these reasons, it 
is difficult to make inferences about these relatively high frequencies. 
Patient Survival 
The discussion of patient survival should be prefaced by an important qualification. 
Given the retrospective nature of this research, it was not possible to distinguish stage 4 patients 
more thoroughly using Karnofsky performance scores or other wellness metric scales that 
evaluate physical functionality/disability. Therefore, if the composition of stage 4 patients 
changes over time (e.g., more "relatively-well" stage 4 patients with Karnofsky score >40 present 
at hospital), the median survival estimates reported here may not accurately reflect stage 4 life 
expectancy. 
With that caveat, the median sll}"Vival of stage 4 patients (see Table 6) remains quite low 
and the confidence intervals around this estimate are relatively small. It is unclear as to whether 
this low survival is a result of ineffective clinical interventions or whether these patients were 
terminal/moribund upon presentation. In either case, the high costs of investigations and 
treatment medications may represent a poor use of scarce health care resources for patients who 
initially present at stage 4. 
Unfortunately, survival of patients in stage 3 and those that progress from stage 3 to 4 is 
more difficult to characterise. These estimates have larger confidence intervals and are more . 
sensitive to the coding method used to assess patient stage. For these reasons, it may be 
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inappropriate to extrapolate from these estimates or to use them in other cost calculations or 
expenditure modelling projections. 
Even with the qualifications to these survival estimates, it appears that GFJ inpatients 
have a much lower survival period than stage 3 and 4 outpatients followed through GSH 
outpatient specialty clinic (data not shown). At GSH, stage 3 patients had a median survival of 
approximately 28 months and stage 4 patients had a median survival of about 17 months.S3 
Clearly, then, the GFJ patients are either much more advanced in HIV disease and/or are 
clinically managed in a less effective manner. ttttt 
Patient Transfers/Referrals 
Large numbers of patients in each stage are transferred to other state health facilities (see 
Table 7). GSH transfers occurred relatively quickly, while those to BCH may have had to be 
delayed until beds there became available. This supply-side issue may be a large factor in the 
difference in stage 3 and stage 4 mean LOS as transfers for stage 3 hospitalisations tend to be to 
BCH while those in stage 4 are more likely to GSH. If BCH turnover improves and beds are 
more quickly made available, patients in stage 3 would likely spend less waiting time at GFJ 
hospital, thereby lowering the stage 3 mean LOS. 
The provincial medical system has a sizable fiscal incentive to minimise the additional 
LOS at GFJ once a patient has been placed on the waiting list at BCH. The recurrent cost per 
patient day at BCH during 1997/98 was R149, while the recurrent cost per patient day at GFJ in 
the same period was R622. mu Assuming that the quality of care for chronic illness is at least as 
good as BCH as at GFJ, the province should seek to maximise the availability of BCH or 
equivalent facility§§§§§ beds in order to expedite inpatient transfers. 
There are two principal options for increasing BCH or equivalent facility bed availability. 
The first is to simply increase capacity at BCH or similar facilities. If the waiting time for BCH 
beds consistently exceeds several days;····· then increasing the bed capacity at BCH and/or at 
other facilities may prove cost saving. 
ttttt While both may be true, clinical audits (including post-mortems when necessary) would be required to 
conclusively determine whether the clinical care afforded to GFJ patients is appropriate and effective. 
mu Cost per bed day for GFJ reported here includes medications, investigations, and laboratory costs as reported by 
the M Blecher, Western Cape Provincial Administration. Please see Appendix F. Costs per patient day at BCH are 
less expensive chiefly because of a lower staff to patient ratio. " 
§1m DP Marais Hospital (formerly Princess Alice Hospital) near Wynberg would be considered an equivalent facility 
to BCH, though it does not provide care for multiple-drug resistant TB (MDR-TB) patients . 
•••••• Dr P Morris, the Medical Superintendent at BCH, suggests that the waiting times usually far exceed one week, 
though they fluctuate over time and differ for men, women, children, and type of care required. 
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The second option is to reduce the number of terminal/moribund patients who are 
transferred to BCH in order to decrease waiting times for other, non-terminal patients. In a small 
informal sample of HIV-infected patients at BCH (n=54), I found that the six-month mortality 
rate exceeded 35 percent. tttttt This high rate suggests that BCH may often provide palliative care 
for late-stage HIV inpatients, which may effectively "crowd out" other patients and extend 
waiting times for BCH inpatient beds. However, reducing the number of terminal/moribund 
inpatients at BCH may increase net provincial medical expenditure if palliative care is instead 
provided at secondary hospitals with higher costs per patient day. For this reason, the first option 
allowing a more rapid transfer to GFJ inpatients to BCH of equivalent facility appears preferable. 
Patient Mortality 
A substantial number of patients in this sample died in hospital or within two weeks of 
discharge (see Table 8). However, the mean length of stay among stage 4 patients who died in 
hospital or shortly after discharge is cause for concern. These patients could presumably be 
discharged to home-based care or hospice providers, thereby reducing their LOS. Given the 
availability of high-quality home-based care providers in the communities surrounding GF 
Jooste, this represents a viable alternative to inpatient terminal care. HUH 
Patient Costs 
The major component of inpatient costs at every stage of disease is the general (recurrent, 
non-patient specific) costs. The general costs per inpatient day totalled approximately RSOO, 
while the patient specific costs of investigations and treatment were lower than R150. The 
relative contribution of general and patient-specific costs to overall expenditure per inpatient day 
is presented in Figure I. 
tttttt Data provided by Dr P Morris. 
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Fig 1: Relative Contribution to Total Costs 
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readmission and, as a result, it may inadvertently increase hospital costs. Therefore, LOS should 
not be used alone as a performance measure or indicator of efficiency. 
Several health planners have wrongly argued that reducing LOS for these patients will not 
result in any meaningful savings to the health system. They suggest that the "general" 
expenditures (like those above) should instead be regarded as "fixed," primarily because these 
costs cannot be equated with variable expenses. In this technical respect, these arguments are 
valid. Indeed, the health system may not experience any nominal reductions in expenditures if 
LOS is reduced: empty beds might simply be filled with other patients requiring services. 
However, the expected increase in AIDS diagnoses and the parallel need for AIDS-related 
inpatient services over the next few years will further strain the existing capacity within the 
medical system. Thus, reducing LOS in the ways described above would, in essence, expand 
hospital capacity at a very low marginal cost. Given the available options to enlarge capacity 
(e.g., building new facilities, etc.), the reduced LOS strategy likely represents the lowest 
opportunity cost. Therefore, I characterise any reduction in LOS as a positive "savings" to the 
state hospital system provided that quality of care and health outcomes are maintained. 
Comparing disaggregated costs to those reported by Karstaedt et al (1996) yields several 
interesting contrasts. Perhaps the most striking of which is duration of hospitalisation: the LOS 
among Karstaedt's patients (8.9 days for stage 3 and 10.7 days for stage 4) was substantially 
longer - almost double - than that among patients in the present sample. Not surprisingly, total 
costs per admission (R2,251 and R2,247 for stage 3 and 4, respectively) were correspondingly 
higher. This may be largely due to differences in mortality: Karstaedt reported a six-month 
mortality of only 15% and 42% for stages 3 and 4, respectively, which is much lower than the 
six-month mortality of37% and 86% among stage 3 and 4 patients in the GFJ sample. 
The cost per bed day in the ~taedt study appears low. Once adjusted for inflation, their 
estimate remains about R150 than that for GF Jooste. It is unclear whether this difference can be 
explained by differences in calculation or whether the patient-specific costs at Baragwanath 
Hospital during the period were lower in real terms than those at GF Jooste in 1997. 
Comparing spending between stage 3 and 4 also yield some interesting results. 
In Karstaedt's analysis, the costs per admission on laboratory tests increased from stage 3 to stage 
4, whereas these costs decreased from stage 3 to 4 among patients in this sample (see Table 11). 
Second, the costs for medications increased as patients progressed through HIV disease in , 
Karstaedt's research, though the trend in this sample is unclear: compared to those initially 
presenting in stage 3, the cost for medications was higher among those presenting in stage 4 but 
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lower for those progressing to stage 4 from 3. It is not clear whether these trends are explained 
by the higher mortality among GF Jooste patients or whether they reflect a difference in clinical 
protocols and treatment practice. 
Several similarities between this analysis and that by Karstaedt et al warrant mention. 
First, the proportion of "bed day costs" (approximately 78% of total cost of admission) was 
roughly equal to the proportion of general costs reported here. Second, the proportion of 
laboratory, radiology, and phannacy spending of the total was roughly the same in both analyses. 
Collectively, this evidence suggests that Jooste admissions are much less expensive than 
those at Baragwanath Hospital, a tertiary facility in Gauteng. Also, the data indicated that GF 
Jooste patients have relatively poorer health outcomes. 
It is critical to note that the Baragwanath sample was comprised of those in a separate 
outpatient cohort, which makes any unqualified comparison with GF Jooste problematic. This 
pivotal difference suggests that the availability of consistent and perhaps higher quality health 
care, particularly at a specialty outpatient clinic, may dramatically improve outcomes. This 
finding is consistent with results reported by Maartens et al (1997), Wood et al (1996), Badri and 
Maartens (in press), and Post el al (1996), which are discussed earlier in this section. Combining 
estimates reported by Karstaedt et al (1996) and Kinghorn et al (1996) and adjusting for inflation, 
such care may cost approximately R5,600 and RI6,OOO per patient year for stages 3 and 4, 
respectively, at Baragwanath Hospital. Unfortunately, I am unable to make similar estimates for 
the Western Cape due to the lack of local outpatient tertiary-level utilisation and cost data. 
Expenditure Item Analysis 
The findings in this section are based both on my data and a series of infonnal. 
confidential interviews with local clinicians. The consistency of responses suggests that the .. 
clinical infonnation above is reliable. Given the confidential nature of these interviews, I am 
likewise unable to list the sources. Even with these qualifiers, the GF Jooste Medical 
Superintendent found the findings sensible and reasonably accurate. 
Cost-containment efforts must be prioritise~,. First, administrators should fonnulate plans 
to reduce total inpatient days per patient. Afterwards, they may elect to review individual 
expenditures items. While the patient·specific component represent only a small poz:tion of total 
costs, some savings can be realised in these areas. 
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Within Lab:Chemistry spending, the standard battery of tests (potassiwn, sodiwn, urea, 
and creatinine) were well represented. However, osmolality, iron studies, and liver function tests 
were also large expenditure items. This is somewhat surprising, given that the first is in many 
instances redundant§§§§§§ and the latter two often yield deranged or inaccurate results in patients 
with later-stage HIV disease. Also, creatinine may be redundant if a doctor orders a urea 
chemistry test. 
The Lab:Haematology spending seems reasonable, with one caveat. As one reviewing 
physician noted, the differential count may not provide information that is vital to clinical 
management. Differential counts may be helpful in deciding whether to initiate prophylaxis in 
asymptomatic HIV -infected patients, but the vast majority of patients in this sample presented as 
symptomatic. The value of differential tests is therefore suspect in this context. 
The Lab:Microbiology spending appears somewhat low, particularly given the frequency 
of respiratory infections, gastrointestinal complaints, and suspected meningitic illnesses. Also, 
two clinician reviewers indicated that the use of TB sensitivities is questionable given the low 
underlying rate of multiple-drug resistant (MDR) TB in the Western Cape, which is currently 
about three to five percent. This expense could be justified if clinicians believe that GF Jooste 
inpatients are disproportionately"MDR-TB-infected, but no empirical evidence is available to 
assess this question. 
Regarding spending on antibiotics, two physician reviewers noted that amoxil may be 
used in place of augmentin (a broad-spectrwn antibiotic) for chest complaints. There are 
certainly trade-offs in terms of resistance patterns, but the use of less expensive antibiotics such 
as amoxil should be encouraged where clinically appropriate. Also, as a minor point, the oral 
(PO) dose offlagyl may be better absorbed and is considerably less expensive than the rectal (PR) 
dose listed here. 
In conclusion, individual expenditures items made up only a very small fraction of total 
patient costs (see Table 11 and Figure 1). Clearly, efforts to reduce spending should be first 
directed as total inpatient days per patient. Yet, some small level of savings might be achieved 
with the operational changes described above. 
mm Osmolality can be calculated if a doctor has the results from glucose, urea, sodium, and (if possible) potassium 
tests. 
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Potential Limitations 
This research is inevitably influenced by several sources of error or bias. Several related 
issues warrant particular attention and are explored below. 
A. Sample Bias 
The patient sample is left truncated in the sense that individuals in this population 
required an HIV -diagnosis for inclusion. Some patients were likely tested at antenatal clinics 
(where active surveillance is conducted) or because a clinician presumed that HIV was the 
underlying cause of morbidity. Accordingly, the cost estimates from this study are for patients 
who both seek care and are diagnosed as having HIV-disease at GF Jooste. 
B. Reliability of Clinical Abstractors 
Regarding the data collection, I informally assessed the reliability of data abstraction 
between the two principal abstractors, Y Williams and F McGill. Overall, their abstractions 
reflected a high degree of reliability. Yet, the abstractions did not correlate exactly; this could 
have resulted from (a) abstractor error or (b) the addition oflab reports, etc. in the lengthy period 
between the abstractions. Fortunately, however, Dr Williams abstracted much of the data during 
the winter of 1998, thereby minimising the distortions from time-delays and from multiple 
abstractors. 
I assumed that the ability to diagnosis HIV -disease among clinicians changed little over 
the sample period. However, should their diagnostic acuity improve or otherwise change in the 
future, the estimates derived from this sample may not properly reflect inpatient costs because the 
population under consideration would ~ffer from that here. 
C. Utilisation Outside of GFJ 
The geographic mobility of this patient population is relatively unknown, though many 
providers suggest that patients often travel between Cape Town and the Eastern Cape/former 
,. 
Transkei. For this reason, patients may have accessed health care in other districts or hospital 
regions. Ifwe assume that the mobility of our patient population remains relatively constant over 
" 
time, our cost 'estimates remain valid for the Western Cape provincial medical system. Should 
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patients become less mobile and communities become more static, however, the level of 
utilisation from the provincial medical system would consequently increase. 
Some patients in our sample might also have received care from outpatient clinics or other 
hospitals within the state system or, more rarely, through private providers. As with access to 
antiretroviral medications, though, the geography and economic status of our patient population 
makes it unlikely that many utilised private health care. Further, given limited transportation, I 
assume that most patients receive their secondary level care primarily from their geographical 
zone provider (GF Jooste). The effect of these phenomena is probably small, though the effect 
would be an underestimation of health care utilisation. 
D. Underestimates of Utilisation 
If patients report different nanies (e.g., Xhosa and Anglicised aliases) at different 
admissions, then they may have duplicate files in which their admissions are separately 
documented. It is difficult to assess the magnitude of this phenomenon, and thus, we may have 
captured only a portion of the utilisation for some of the 30 patients who gave Anglicised first 
names. 
Also, due to shortcomings in our data sources, we may underestimate actual pharmacy 
utilisation. This may occur for three principal reasons. First, the 'drugs dispensed from ward 
stock may not be consistently noted in the patient's folder. Second, the scripts written at time of 
discharge may not be included in the patient's records. Indeed, few such scripts were recorded in 
the charts, which seems particularly strange given that a large proportion of patients required 
ongoing anti-TB medications. Third, we assumed that patients received the balance of their 
prescriptions through the outpatient pharmacy at time of discharge. This assumption is 
problematic as doctors may write a ~ script for the entire treatment course or prophylactic 
prescription instead of the balance from the original inpatient script. (personal communication, 
Sr Liz Fielder, Dr Roy Breeds, Dr Douglas Wilson, 15/9/99) However, there does not seem to be 
consistency in this practice. (personal communication, Drs Breeds and Wilson, 15/9/99) 
We may also slightly underestimate laboratory and radiology utilisation. In our 
abstractions, we counted only those lab tests for which the results were reported and stored in the 
chart. Tests may have been ordered and no results received. In like fashion, we exclude x-rays 
that were ordered but for which results are not reported. These phenomena are partiCUlarly 
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confounding among those patients who died in hospital as it is not clear whether the hospital staff 
perfonned the tests, radiological exams, and so forth prior to the patient's death. 
It is important to note, however, clinicians were most likely to document the more 
expensive items because these tests or procedures were also the most clinically relevant. For this 
reason, the undocumented lab tests, etc. are probably among the least expensive. 
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Despite the limitations discussed above, this research provides the basis for the several 
conclusions and policy recommendations. While I focus my conclusions and suggestions on 
clinical care issues and hospital operations at GF Jooste, I also address several system-wide 
within the state health care structure. 
Based on this study, I recommend the following: 
1. Increase the use of co-trimoxazole prophylaxis in stages 3 and 4 of HIV disease. 
Prescriptions of co-trimoxazole among patients in our sample, all of whom were 
symptomatic or in advanced disease, were strikingly low (see table 4). Yet, this inexpensive 
antibiotic represents one of the few feasible drug interventions that alter the course of HN 
disease. Greater use of this daily-dose prophylax~s by clinicians would extend the life of many 
patients. 
A ward-based co-trimoxazole program can be implemented with relative ease. Consistent with 
the forthcoming Treatment Guidelines, all HN inpatients 
• at WHO stage 3 or 4; or 
• with tuberculosis; or 
• presenting with pyrexia unknown origin (PUO) or unexplained weight loss··· .. •• 
should be discharged with at minimum one month's supply of co-trimoxazole tablets and be 
given a letter of referral for day clinics at which the prescription can be refilled. These letters can 
be pre-printed and be made readily available for the medical officers so that the MO's can 
complete them quickly. 
As part of this effort, medical superintendents also must raise awareness about the 
importance of co-trimoxazole prophylaxis. Workshops on adherence counselling should be 
included as part of the training for medical students and as part of continuing medical education. 
In addition, posters should be put up in the wards and at nurses' stations to remind clinicians of 
the value of this vital intervention. 
The medical superintendent should also consider advocating for a specialist mv OPD 
clinic as part of the new GF Jooste outpatient facility. Through a weekly specialty clinic, 
prevention/prophylaxis interventions that begin at GF Jooste Hospital can be sustained on an 
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outpatient basis after patients are discharged. As mentioned in the Discussion section, the 
evidence from Baragwanath as reported by Karstaedt et al and several local studies suggests that 
improved health outcomes may be related to access to such specialty care. 
2. Review treatment protocol for patients initially presenting at WHO stage 4. 
Based on these sample data, I conclude that the current practice of treating patients who 
initially presented at WHO stage 4 is unsustainable and must be reviewed. The expenditure 
incurred to treat these patients did not appear to extend their lives (see Table 6). However, it is 
unclear whether patients who initially presented at stage 4 were terminal/moribund upon 
admission (according to laboratory surrogate markers, Kamofsky score <40, etc.) or whether a 
poor quality of care contributed in part to the low median survival. For this reason, I suggest that 
medical superintendents conduct clinical audits to determine the degree to which aggressive, 
high-quality therapeutic interventions would alter this survival pattern. Based on these results the 
clinical staff can decide how patients who initially present at stage 4 can best be managed or 
discharged to alternative hospice or home-based care services. 
3. Focus on pain management/palliative care education among clinicians. 
Pain management and palliative care is not often considered an acceptable alternative to 
aggressive clinical intervention for late-stage patients. However, making the patient more 
comfortable in the terminal stages of disease is an essential component of their clinical 
management. Accordingly, the most recent HIV Clinical Practice Guidelines for the province 
have begun to stress the importance of pain management and palliative/terminal care medicine. 
Unfortunately, however, there is a general lack of knowledge in pain management and 
terminal care among many local clinicians. For this reason, medical superintendents should work 
with the other academic hospitals to include training in this area for medical students and 
incorporate these issues as part of continuing medical education for other clinical staff. 
Dissemination of the forthcoming HIV Clinical Practice Guidelines and instruction in their use 
should be made a priority. 
4. Better utilise home-based care alternatives for terminal/moribund patients • 
••••••• These symptoms are indicative of tuberculosis. 
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The only immediate option for reducing inpatient hospital days is to make better use of 
tenninal and home-based care options for patients in late-stage HIV disease. Fortunately, several 
local NGO's (particularly the Red Cross Society) provide high-quality care in this respect. 
Medical superintendents should better network: ward MO's with these agencies. In this way, 
appropriate home-care referrals and transfers can be made quickly and inpatient days for 
termina1Imoribund patients can therefore be minimised. Also, referral forms should be kept 
readily available at nurses' stations and NGO staff should be invited to present information to 
clinical staff. 
S. Reduce specific laboratory/antibiotic utilisation. 
While laboratory costs constitute only a small proportion of total inpatient expenditure for 
HIV, this spending can, in certain circumstances, be reduced. In particular, clinicians may need 
to reconsider orders for iron or liver function tests in later-stage HIV disease as the results from 
such tests are often deranged. Further, the use of differentiaJiCD4 counts is suspect unless the 
M.O. finds them to be of clear clinical relevance. Additionally, the use of more expensive, broad-
spectrum antibiotics should also be examined. Where clinically appropriate, less expensive 
antibiotics such as Amoxil should be used over Augmentin and others. 
However, the respective savings from these items are comparatively small. Hospital 
administrators should therefore prioritise reducing length of stay and training in palliative care 
before focusing on specific expenditure items. 
6. Increase bed availability at non-acute, chronic care facilities 
Delays in the transfer of inpatients from GFJ to BCH have substantial direct costs, 
particularly as the cost per patient day is roughly R470 higher at GFJ. With large BCH capacity, 
patients could be more rapidly transferred from acute secondary facilities. Because the present 
waiting time for a bed at BCH is in excess of one week, these savings from increasing the number 
BCH or equivalent facility beds could be substantial. ttttttt 
ttttttt Dr P Morris notes the BCH waiting list has recently grown even longer, particularly because D.P. Marais 
Hospital is nO longer caring for multiple-drug resistant TB and transfers such patients to BCH. 
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There are two principal options for increasing bed availability BCH or equivalent 
facilities. The first is to simply increase capacity. The second option is to reduce the number of 
tenninallmoribund patients who are transferred to BCH in order to decrease waiting times for 
other, non-tenninal patients. 
The first option appears preferable. Reducing the number of tenninallmoribund inpatients 
at BCH may actually increase net provincial medical expenditure, mainly because such patients 
are likely to be readmitted to more-expensive secondary hospitals. For this reason, the province 
should consider expanding patient capacity at BCH or equivalent facilities. 
7. Bridge the current gaps in information technology. 
Future information technology efforts should focus on two key areas. First, patient 
records such as the infection control book should be stored electronically, using Access or similar 
database application. A computer for this purpose has been provided to the Infection Control 
Sister, though proper training of staff is required before the PC will be used effectively. Second, 
laboratory and prescription data should be linked to patient database. These improvements would 
(a) allow clinicians to access past patient care infonnation that is missing from the chart and (b) 
simplify hospital statistics and record keeping. Additionally, the easy download of such 
infonnation in a database would enable future researchers/evaluators to replicate this type of 
exercise with greater accuracy and with considerable time-savings. 
8. Introduce unique patient identifiers (UPIs). 
The introduction of unique patient identifiers (e.g., Home Affairs-issued ID numbers) 
across all facilities/agencies is essential. In this way, a patient would be identified by the same 
UPI at every facility in the state medical system. These identifiers would replace the current 
systems, which assign patients different folder numbers in each clinic and hospital. The UPIs 
would greatly assist the integration of existing databases (e.g., phannacy, laboratory, and 
admissions) across facilities and improve the continuity of care for patients who access services 
from different levels within the provincial medical system. In addition, the use of UPIs would 
greatly assist with the tracking of patient utilisation and mortality; the current system of different 
folder numbers, etc. severely inhibits research and evaluation in this area. 
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9. Improve documentation in patient charts. 
Substantial amounts of laboratory test results and radiological procedures appear to have 
been ordered, but the results where never documented in the patient notes or later inserted in the 
patient files. Considerable expenditures were therefore incurred, but they did not seemingly 
contribute to or improve the clinical management of patients. While no operational 
recommendations can be made on the basis of this study, it is clear that this issue deserves much 
greater attention. 
One specific issue does warrant mention. At the rear of the admissions/folders office 
outside the Casualty Department, several large boxes of laboratory results remain as though 
discarded. It may be impractical to file all of these individual and somewhat dated results, but at 
minimum, this practice should be halted. 
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VIII. SUGGESrlONS FOR FURTHER RESEARCH 
The following areas of research would yield infonnation that would improve the accuracy of the 
cost, utilisation, and other estimates: 
• geographic mobility of this patient population (frequency and duration of trips, 
specifically to the Eastern Cape); 
• consistency of utilisation from the geographic zone hospital provider; and 
• costing of chest-x-rays and other common radiological procedures within the state 
medical system. 
Further, other cost components of HIV care have not been investigated in this province. Local 
outpatient utilisation at both the primary care level and tertiary care/specialty clinic utilisation 
remain unquantified. For a more comprehensive estimate of the costs of HJV-care to the state 
medical system, these issues must be explored. 
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Appendix A: 
Table of Cost Studies 
- I 
Table: HIV Cost Studies from the U.S. 
Data collection through 12-May-97 
Andrulius 92 
Data 
The article reports data for hospitalized pts.: 
AIDS OHIV Total 
1. no. of pts. 16,213 11,077 27,290 
2. LOS 16.4 14.4 15.7 
3. Days per pt. per /yr. 28.4 19.4 24.7 
4. admiss. per pt./yr. 1.7 1.3 1.6 
Costs (SD): 
per day 785' 689 757 
(196) (180) (350) 
per admission 10,998 8,413 10,156 
(6,037) (6,550) (6,720) 
per pt. per yr/ 18,487 11,010 15,621 
(10,198) (8,299) (10,779) 
The article reports charges and revenue figures similar to the data given above for 
costs. 
Notes 
The article reports data by the 1987 AIDS 
definition but also uses "other HIV illness" 
category. They authors suggest that this will 
help with comparisons using the '92 definition. 
Fleischman 94 Six-month utilization of a variety of medical services is reported by disease status: (1) Study uses 1987 AIDS defintion. 
AIDS, (2) symptomatic, and (3) asymptomatic. "Symptomatic" means that patient had 
some symptoms but no AIDS diagnosis. 










In-pt. admissions 2.1 0.7 0.5 
(1) (0) (0) 
In-pt. avg. LOS -- -- --
(9) (6) (5) 
In-pt. nights 27.4 5.9 5.6 
(1) (0) (0) 
Emergency rm visits. 2.3 1.1 0.8 
(1) (0) (1) 
Also reports proportion of those in each disease state which had an in-pt admission, 
emergency room visit, and/or amublatory care. 
Article reports monthly ACSUS cost data for: 
(a) AIDS (,87 definition) 
(b) CD4s<200, no AIDS 
(c) CD4s 200-500, no AIDS 
(d) CD4s>500, no AIDS 







(a) (b) (c) (d) 
$ 1890 (68) 456 (46) 119 (28) 54 (19) 
380 (14) 344 (35) 191 (44) 151 (54) 
174 (6) 80 (8) 21 (5) 10 (4) 
265 (10) 110 (11) 99 (23) 67 (24) 
55 (2) 0 0 0 
Parentheses = proportion of total 
6. Total 2,764 990 430 282 






Parentheses = 95% CIs 
Three-month costs for decedents and survivors, listed by medical service categories. 
Ambulatory medical visits: 
Emergency room visit: 










Numbers do not sum to total due to rounding. 
Medi-Cal AIDS expenditures under different definitions: 
91192 92193 
Pre-1993: $ 2,048 2,019 
1993 Defintion 965 956 
Data for 1986-90 is also listed. 
89190 90/91 9192 92/93 
In-pt. expend/day $ 706 737 798 785 
Avg. LOS (days) to.3 9.9 9.3 8.2 
Also reports useful non-medical service utilization data. 
Reports monthly Maryland Medicaid expenditures for pts wI CD4s: 
(1) 51-200 
(2) 201-500, and 
(3) >500. 
Found that monthly Medicaid payments were not sig. different for the CD4 groups (2) 
and (3). This is likely due to the fact the OIs are more common ifCD4s < 50. See 
attached chart for costs by CD4 group. 
Study uses 1987 AIDS definition. 
60% of pts. in study were IDUs and were 86% 




Reports (a) % with emergency room visit, (b) % with in-pt. admission, and (c) number 
of out-pt. visits for: 
1. AIDS pts. 
















$ 261 (rep. out-pt. + emergency rm) 
$ 241 (56% of total) 
$ 20 
$ 165 (38% of total) 
(all figures apparently in 198~ dollargs) 
Mean of 0.04 monthly hospitalizations per pt. which lasted an average of 4.1 days and 
incurred a mean charge of$4,297. 
25% of out-pt. charges were for pharmacy costs. 
Utilization per person-year of (a) admissions, (b) in-pt. days, and (c) out-pt. clinic visits 
by the following categories: 
1. CD4s < 50 
2. CD4s = 51-200 
3. CD4s = 201-500 
















Rietmeijer 93 Year-long utilization of services (1990) A different rate of death (not reported) may 
affect the utilization and costs associated with 
AIDS pts. (n = 274) each category. Also, data is given for non-
Hospitalizations per pt.: 0.86 AIDS pts. with CD4s >200. 
- Days per hospitalization: 8.2 
Charges per day: $ 1,349 Also, this study uses1987 AIDS defintion. 
Charges per pt.: $ 9,588 
If we use a weighted average of the data 
Out-pt. visits1 per pt.: 23.7 presented for AIDS and that given for patients 
Charges per visit: $ 345 without AIDS who have CD4 < 200, we may 
Charges per pt.: $ 8,177 arrive at reasonable numbers for 1993 CDC 
definition ofpt. WI AIDS. 
Total charges per pt.: $17,765 
., 
Results wi weighted average 
Non-AIDS pts. w. CD4 <200 (n = 77) Hospitalizations per pt.: 0.75 
Hospitalizations per pt.: 0.36 Days per hospitalization: 8.7 
Days per hospitalization: 10.4 Charges per day: $ 1,540 
Charges per day: $ 2,221 Charges per pt.: $ 9,325 
Charges per pt.: $ 8,392 
Outpt. visits' per pt.: 21.9 
Outpt. visits' per pt.: 15.4 Charges per visit: $ 330 
Charges per visit: $ 278 Charges per pt.: $ 7,322 
Charges per pt.: $ 4,294 
Total charges per pt.: $ 16,648 
Total charges per pt.: $ 12,686 
Ruane 97 Comparing July-Dec 94 with Jan-June 96, researchers at Tower clinic in LA found: 
1. hospital days per pt. month fell from 3.36 to 1.28 
2. skilled nursing/hospice days fell from 136.8 to 48 
3. HHC: mean pt. # receiving fell from 67.6 to 28.7 (58%) 
• Oupatient figure does not appear to include emergency room charges 
Torres 97 
Specific therapies and out-pt. referrals for various procedures fell as well. Data 
reported in 4th ROI abstract 
"The Body" reported that Ruane had found: 
I. 56% reduction in hospitalization and HHC 
2. 80% ofpts. experienced rise in CD4 ct. in 96 as compared to 95 
3. Fewer pts. have <50 CD4s: 17.3% in 96 as compo to 28.5% in 95. 
Reported data from St. Vincent's Hospital in NYC: 
1. Ambulatory visits by HIV -positive pts. increased 33% from 95 to 96 (includes 
visits for HIV testing & counseling, early intervention services, primary medical 
care, etc.) 
2. Pts. seen in out-pt. clinc increased 21 % from 95 to 96. 
3. In-pt. census dropped by 27% froim 94 to 96 (24% from 95 to 96 alone). From 95 
to 96, admissions fell by 10.5%, discharges fell by 9.4%, in-pt. days fell by 23.6%, 
and avg. LOS fell by 15.9% 
Expenditures for all drug Rx' s were reported 
only through October 96. Yet from Jan. to 
Oct. 96, ZDV, d4T, and 3TC costs increased to 
levels excedding that of saquinavir. Even 
though PIs were available only in July 96, we 
would expect the total expenditures for these 
drugs to be larger than others due to the much 
higher unit costs. As this is not the case, it 
seems likely that this clinic frequently 
prescribed dual therapies. This makes it 
difficult to entirely attribute the clinical 
responses to protease drugs. 
1\1ourc-Ollla by CD4 Lc-\'el 
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Appendix D: 
Other Diagnoses 
"OtherH Discharge Diagnoses (total caHIll 
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Sert"'" Slep.Jepsy , , 
Rectal bleedongilisSUles , 
FOOQworm (diffuse) , 
Seborrhoeic dermal,lls , 
Trauma legWO<.nd , 
" "OIMt~_·"'T_."""''''''~'''''_'''~"""_,, .. 
Appendix E: 
Total Patient Spending 
Gross Expenditures (nurH1olel costs onl),,: 1111 hOSI!Mhtabons 11'1 swnpte) 
Inlllaity WHO Inlll~tly WHO Trlll&fer 10 
SI~gG 3 Stage 4 Stage 4 from 3 
lib Tests 12.387.09 4.394.14 1.631.13 
C'U,!lI1IStry 5.45584 1.69449 1.33168 
HaemaloJogy 1.349 n 34276 1640 
MJcrobi%t,;y 3.144 49 
"" 25 
27589 
serology 2,40260 1.51864 1416 
""~ "" 
OlagnO&IIC Procedures 405.10 69.00 "" 
Radiology 3.1(19,50 1.904.50 171.60 
Medications. ek- 1.185.10 5.963.90 3,394.46 
Analgesics, ere. 102 11 4387 12085 
AnrHt.SrhrnallC.t. erc 381 24 10,23 6602 
AnIIbtOllC5 {exCl TB drugsl 1.693.30 3.24085 61297 
Anll4unga/& 00'95 "3549 12505 
Anl" TB 26172 93,69 117,94 
F""",",,,,,,, 5.623,13 1.76141 1. 12716 
"'"". 213 96 "26 133 14 VllarrunlMlner8Js 14139 56" 24733 
Ml$CefiJll9OUS 253 24 23565 84400 -- 4235 -- OS, 026 310 ........... 11<:1 63,13 184 23 166 02 
0,60 056 
~-- 14 12 22" .. - 9093 3825 632 83 
~ 326 .... "" 1292 "" 
h Procedures. elc.: 291 HI 35.30 
TOTAl 24.918.59 12.366,84 5.245.29 
Appendix F: 
BCH Cost per Patient Day 
BCH cost/day calculat ion for 1997198 
aCH eop ~reeurl'flnt) 
INP days" 
OPO V1SItS 
CAS ... s.a 
OPO, CAS 'lIo oI lNP 
PerSO"Vlel 
A(lmonstranve 
Store If, lr,oestocl< 
Equ.pment (e~c1 Cap) 




Total (Recurrent Noo-S~fIc) 
T O!aI (RlKU'rant • Cacotal) 
15,:)96.232 
t03.23{1 
'" 
12.390.644 
196.46l; 
2.141,485 
46 ,305 
44:),053 
178,079 
15.396,232 
666.666 
14.729.566 
80.356 
15.476,588 
